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Abstract/Executive Summary
Problem statement
The goal of this project is to improve our understanding of nucleic acid interactions
with cationic polymers with the theory that the polymers could protect the nucleic acids from
degradation caused by biological enzymes. We seek to understand what the limitations of the
cationic polymers are which, in this case, is mainly polymer-DNA compatibility. This
experiment utilized peptide-dextran hybrid polymers with differing functionalizations to
condense anionic nucleic acids into nanometer-sized polyplexes. Techniques of dynamic light
scattering and zeta-potential were utilized to determine the particle sizes and surface charges
of polyplexes.
Results and Conclusions
In this experiment, dextran with a molecular weight of 20 kDa was used. The dextran
was then functionalized in four combinations: R 3H3C or R5H5C conjugations each with and
without CB-functionality. Additionally, N/P ratios of 0, 1, 5, 10, 20, and 30 were tested for
each combination. The results, quantified in Tables 1 to 4, and summarized in Figure 10 and
Figure 11 near the end of this document, indicate dextran polymer compatibility with DNA
improves with the addition of CB-functionality, using the larger R 5H5C peptide over R3H3C,
and increasing N/P ratios.
Implications and Recommendations
This project could potentially be used in future gene therapy projects as we have taken
steps towards understanding what tweaks can be made to improve nucleic acids interactions
with cationic polymers. We have also gained experience in properly using lab equipment, a
much better insight into the difficulties of synthesizing materials, especially when working
with extremely small quantities, and we have observed the detrimental effects time constraints
have on data quality. In light of knowledge gained from dealing with the difficulties
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encountered, it is recommended that this experiment be repeated under less time pressure to
obtain better data.
In the future, we recommend trying different molecular weights of dextran in addition
to varying the degrees of CB-substitution, and possibly using a greater variety of peptides (i.e.
lysine in place of arginine). Performing titrations are also highly recommended as the zetapotentials are highly impacted by pH.
Advice to Students
My advice to students looking to undertake similar work is to be aware of the
difficulties of dealing with extremely small quantities of reagents, especially regarding the
sensitivity of the results. Additionally, expect to repeat synthesis steps for it is rare for things
to go right on the first try. A good rule-of-thumb is to take the estimated time required and
multiply it by three.
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1. Introduction
The purpose of this project is to develop a better understanding of nucleic acid
interactions with cationic polymers. The theory driving this project is that the polymers could
possibly act as a “bodyguard” by protecting the nucleic acids from degradation caused by
biological enzymes. Therefore, it is crucial to understand the limitations of the cationic
polymers under various physiological conditions (i.e. the amount of DNA the polymers are
capable of holding, the tenacity that the polymer hangs on to the DNA, polymer-DNA
compatibility, etc.).
This experiment utilizes cationic (positively charged) polymers to condense anionic
(negatively charged) nucleic acids into nanometer-sized polyplexes. In order to investigate the
interactions of the nucleic acids with the polymer, we utilize techniques of dynamic light
scattering to determine the particle sizes and surface charges of polyplexes in addition to
agarose gel electrophoresis to determine the particle sizes, surface charges, and the binding
strength of the polyplexes formed under different physiological pH conditions.
This project has the potential to be utilized in future projects regarding gene therapy as
the cationic polymers promote nucleic acids to enter cells. Such applications are of
significance due to the proven ability of gene therapy to cure hereditary diseases, such as
SCID-X11, and some forms of cancer. Utilizing the polymers as a non-viral vector for gene
therapy, the costs and risks could potentially be lowered thereby increasing the accessibility
of gene therapy. By undertaking this project, we hope to determine the possibility and
feasibility of such outcomes with a better understanding of how nucleic acids interact with
cationic polymers.
2. Background Information
By definition, gene therapy is “the transfer of new genetic material to the cells of an
individual in order to produce a therapeutic effect”. 1 On paper, gene therapy is rather simple
and can be summed up as manipulating deoxyribonucleic acid (DNA) in the genome using
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vector carriers, analogous to replacing defective parts on a piece of machinery where the
DNA is the part, the genome is the machinery, and the vector is the tool that gets the job done.
However, the reality of gene therapy was discovered to be much more complicated in
practice.
Such evidence demonstrating the complexity of gene therapy was observed in the only
documented gene therapy success in humans that treated children with severe combined
immunodeficiency disease (SCID), or more specifically, the SCID-X1 form. Children with
SCID are required to be isolated in a sterile environment because they will receive fatal
infections otherwise, hence their nickname of “bubble babies”. This is due to inheriting a
faulty gene that encodes the γc cytokine receptor that is essential for the immune system to
function properly. The cure involved incubating bone marrow cells with a viral vector that
replaced the defective γc cytokine receptor gene with a functional one then returning the
incubated bone marrow cells into the body. While this treatment restored the function of their
immune systems, however, two of the children developed leukemia resulting from of this
treatment. Mishaps such as these occur due to the use of viral vectors that indiscriminately
integrate the genetic material into the genome.1
As mentioned previously, there are plenty of issues confronting gene therapy. One of
the largest issues is that the “surgical strike” is rather elusive and is rarely clean and effective
as the theory suggests.2 In addition to precision, the success of gene therapy also depends on
safe and efficient gene delivery systems that offer: DNA protection, cellular uptake,
endosomal escape, and low toxicity. 3 Of the myriad of delivery systems available, all of them
can be narrowed down into two groups: viral vectors and non-viral vectors, 3 each with their
advantages and disadvantages.
The main problem with non-viral vectors is lower efficiency in comparison to viral
vectors, but they are usually safer because they avoid problems associated with viruses such
as immunogenicity, “insertional mutagenesis”, which is what occurred with two of the SCID5

X1 patients to cause development of T-cell acute lymphoblastic leukemia as determined by
U.S. and French investigations,2 and complexity of production.3 On the other hand, non-viral
vectors, which can induce high gene transfection in vitro, are typically comprised of synthetic
materials such as cationic lipids, polymers, and dendrimers. As a result, non-viral vectors
usually suffer from additional problems of toxicity, non-biodegradability, and often exhibit
poor biocompatibility when used in vivo.3
In light of problems faced by non-viral vectors, previous research indicates that a
dextran-peptide hybrid polymer may be a suitable non-viral vector in the future for a safe and
efficient gene therapy delivery system. 3 Considering the historical applications of dextran by
itself, it should come as no surprise that dextran would be suitable for gene therapy.
For example, one of the best-known historical applications of dextran was as a blood
plasma volume expander during the Korean War. In 1952, dextran was approved by the
Surgeon General for use on battle casualties in the Korean War and it was here that dextran
was first administered intravenously as a substitute for blood plasma and became credited
with saving thousands of American lives during the war.4 Prior to this, it was pioneered by the
Swedish in an investigation during 1944 and 1945. Shortly afterwards, a 6% solution of a
dextran fraction was approved for clinical use in Sweden in 1947 5 and an estimated 20,000
units had been administered to Swedish patients by 1949. 6 Also, in addition to being used as a
blood plasma volume expander, dextran was also used as an anti-coagulant which came about
as a result of observations during blood plasma substitution trials where dextran was
determined to be the cause for a bleeding tendency upon its administration. From this
observation, dextran was used as a means to prevent arterial and venous thrombosis.7
3. Materials and methods
3.1. Materials
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N,N-Dimethylglycine ethyl ester (DMGEE, CAS 33229-89-9, M W=131.17, ρ=0.93)
manufactured by Tokyo Chemical Industry Co., LTD. (6-15-9 Toshima, Kita-Ku, Tokyo,
Japan).
Sodium hydroxide (NaOH, CAS 1310-73-2, MW=40.00, bp=1,390°C, mp=318°C,
ρ=2.1300) manufactured by Sigma-Aldrich Co. (3050 Spruce Street, St. Louis, MO 63103
USA).
Dextran (Dex20, CAS 9004-54-0, MR=15-25 kD) manufactured by Sigma-Aldrich Co.
(3050 Spruce Street, St. Louis, MO 63103 USA).
Epichlorohydrin (ECH, CAS 106-89-8, MW=92.53, Fp=32°C(89.6°F), bp=115-117°C,
mp=-57°C, ρ=1.18) manufactured by Sigma-Aldrich Co. (3050 Spruce Street, St. Louis, MO
63103 USA).
Glycidyl methacrylate (GMA, CAS 106-91-2) manufactured by Sigma-Aldrich Co.
(3050 Spruce Street, St. Louis, MO 63103 USA).
Methylsulfoxide (DMSO, CAS 67-68-5, MW=78.14) manufactured by EMD
Chemicals Inc. (480 S. Democrat Rd., Gibbstown, NJ 08027 USA).
4-Dimethylaminopyridine (DMAP, CAS 1122-58-3, MW=122.17) manufactured by
Oakwood Products Inc. (1741 Old Dunbar Rd., West Columbia, SC 29172 USA).
Hydrochloric acid (HCl, CAS 7647-01-0, 1.0M Solution) manufactured by Ward's
Science Plus (5100 West Henrietta Rd., Rochester, NY 14692-9012 USA).
Spectra/Por®3 Dialysis membrane standard RC tubing (MWCO=3.5 kD, Nominal flat
width=54 mm, Diameter=34 mm, Vol/Length=9.3 mL/cm).
Water purified using a Millipore Milli-Q Direct 8 Ultrapure Water system (Billerica,
MA, USA) and filtered through a 0.22 μm Millipak® filter.
The R3H3C and R5H5C peptides were synthesized by GenScript (Piscataway, NJ).
pCMV-Luc DNA was manufactured by Elim Biopharmaceuticals (Hayward, CA).
Methacrylate functionalized dextran was synthesized in a previous work in May 2013.
7

3.2. Synthsis of CB-functionalized dextran (Dex-CB)
Dimethylglycine ethyl ester (DMGEE) was hydrolyzed prior to its addition to dextran.
DMGEE was hydrolyzed in an aqueous solution containing an equimolar amount of sodium
hydroxide overnight at 50°C. The ethanol byproduct was then separated by means of vacuum
evaporation using a Heidolph Hei-VAP Value “The Collegiate” rotary evaporator (roto-vap).
Afterward, this dried product was dissolved in water and briefly placed under sonication prior
to reacting with dextran and epichlorohydrin. This reaction was allowed to proceed over the
course of two days under elevated temperature at 55°C. The CB-functionalized dextran
product was then isolated by means of dialysis against water through a cellulose membrane
with a 3.5k cut-off over the course of three days with manual daily water change cycles.
Upon completion of the dialysis, the product was then lyophilized (freeze-dried) by
first freezing at -80°C in a VWR freezer unit prior to transferring to a Labconco FreeZone 4.5
freeze-dryer vacuum. The product remained under vacuum until all the water sublimated
which took about 2-4 days.
In order to increase the degree of CB substitution, the above procedure was repeated
where freeze-dried CB-functionalized dextran was used in place of pure dextran after the rotovap step.
3.3. Synthsis of MA-functionalized dextran-CB (Dex-CB-MA)
The next segment involved adding a methacrylate (MA) group to the CBfunctionalized dextran (Dex-CB) polymer backbone. This MA functional group provides the
double bonds that allow the cysteine residue on the peptides to bond.
First, the CB-functionalized dextran product was placed in a 2-neck flask and
completely dissolved in dimethyl sulfoxide (DMSO) under a nitrogen atmosphere at 90°C.
Upon the completion of the dissolution, the solution was cooled to 33°C where 62.5 mg per
250 mg dextran of 4-Dimethylaminopyridine (DMAP) catalyst and 0.6 equivalents of glycidyl
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methacrylate (GMA) were added. This reaction was then allowed to proceed under a nitrogen
atmosphere for two days prior to undergoing dialysis against water.
3.4. Synthesis of dextran-peptide hybrids (Dex[-CB]-RxHxC)
In order for dextran to “grab” the DNA, it needs a positively charged moiety such as
that provided by the arginine and histidine residues in the peptide. The first step for
functionalizing dextran with a peptide (either R 3H3C or R5H5C) involves dissolving the
dextran polymer in water. In the next step, water and TCEP are added to the peptide and
incubated for 5 minutes at room temperature. After incubation, NaOH solution is added to the
water/TCEP/peptide mixture until the pH is around 6 (it is initially around 2). Afterward the
water/TCEP/peptide mixture is added to the dissolved polymer, and NaOH is added until a
final pH between 7.5 and 8 is reached.
3.5. Creating the dextran-peptide-DNA polyplexes
In order to determine the interactions between positively charged polymers and
negatively charged DNA, the N/P ratios were varied where N is the number of moles of a
positively charged peptide residue (arginine) and P is the number of moles of a negatively
charged phosphate group on a DNA residue. Samples were prepared for N/P molar ratios of 0,
1, 5, 10, 20, and 30 (40 is incomplete due to time constraints).
The preparation involved creating a 10 mg per mL working solution of the polymer
and diluting 1 mg per mL working solution of DNA with saline solution at a ratio of 1:4
respectively by volume. The polymer working solutions were then further diluted with a precalculated amount of saline solution and combined with the saline-diluted DNA working
solution. These blends were allowed to sit for 20 minutes at room temperature prior to
analysis.
3.6. Determining degree of substitution (DS)
Degree of substitution determination was carried out via 300MHz 1H NMR. To
prepare the sample for nuclear magnetic resonance (NMR) analysis, approximately 10 mg of
9

the freeze-dried product was dissolved in deuterium oxide (D 2O) in a capillary tube. The
NMR results were then analyzed to determine degree of substitution.
NMR spectroscopy works by recording the energy difference between +1/2 and -1/2
spin states, which are directly proportional to applied magnetic field strength. The NMR
spectrum is generated by irradiating a specimen with a certain frequency radiation (300 MHz
for the purposes of this project) and slowing increasing the field strength. Eventually the
nuclei of the molecules in question will absorb RF energy, thus creating a resonance signal
that is recorded and shown in the spectra.8
3.7. Size and Zeta-potential measurements
To prepare the samples for zeta-sizer analysis, the polymer-DNA blends were further
diluted by adding 800 μL of water to 95 μL of polymer-DNA blend to create the final analysis
solution. This final analysis solution was first placed in a disposable cuvette for the Malvern
ZetaSizer Nano ZS (Red badge) for obtaining particle size data. After obtaining the particle
sizes, the sample was then transferred to a zeta-potential cuvette and the zeta-potentials were
measured. In total, five particle size measurements and four zeta-potential measurements were
obtained per N/P ratio for each polymer-DNA blend.
The Zeta-sizer measures particle size by a method called Dynamic Light Scattering
(DLS). DLS works by measuring the intensity fluctuations of diffracted laser light caused by
Brownian motion (motion induced via particle-particle collisions) and correlating it to particle
size via the Stokes-Einstein equation. If a particle is small, the movement will be much
greater than if the particle is large.9
Zeta-Potential is the charge that exists at the plane between the Stern layer (layer of
ions bound to the surface of the particle) and the diffuse region. The Zeta-potential is
determined by measuring the electrophoretic mobility and applying the Henry equation. The
electrophoretic mobility is determined using Laser Doppler Velocimetry (LDV) to measure
the particle velocity when a potential is applied to the system. In short, the Zeta-potential tells
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us how stable the system is and it is heavily affected by pH. The system is most unstable
when the Zeta-potential is zero (isoelectric point) and is considered stable when the Zetapotential is outwith ±30 mV.9
4. Results and Discussion
Dextran with a molecular weight of 20 kD was first functionalized with a carboxyl
(CB) group by DMGEE hydrolysis to yield Dex20-CB(33%) product as determined via NMR
analysis shown in Figure 1. This Dex20-CB(33%) product was further functionalized with
MA by transesterification of GMA to yield Dex20-CB(46%)-MA(99%) product as
determined by NMR analysis shown in Figure 2. The reaction schematic for these steps can
be seen in Scheme 1.
Upon review of lab notes, it was found that the reason for the excessive degree of MA
substitution was due to a calculation mistake resulting in the addition of GMA to Dex-CB
reactant at a molar ratio of 1.5:1 of GMA to dextran. Consequently, this reaction was redone
using a molar ratio of 0.6:1 as originally intended. The result yielded Dex20-CB(35%)MA(90%) as determined by NMR analysis shown in Figure 3. The reason for the repeat of
“impossibly high” DS was due to improper pipette usage – specifically, pushing the plunger
all the way down during the draw step resulting in a larger-than-indicated draw – discovered
later on when preparing the zeta-sizer solutions for Dex20-CB(35%)-MA(90%)-R5H5(80%).
Higher DS CB-functionalized dextran synthesis yielded a product with a DS no higher
than the Dex20-CB(33%) reactant (NMR not shown), so the procedure for increasing CB DS
was re-done. The re-done synthesis ended up yielding a lower DS of 25% as determined by
NMR analysis shown in Figure 4. Excessive NaOH addition is suspected for this enigmatic
result as the NaOH facilitates CB fall-out.
Given the difficulties encountered up to this point and considering deadlines, MAfunctionalized dextran from a previous study was utilized in order to save time by eliminating
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the steps required for the synthesis thereof. An NMR analysis was performed on this
compound and shows that the compound is Dex20-MA(33%) as can be seen in Figure 5.
R3H3C and R5H5C proteins were conjugated to the Dex20-CB(35%)-MA(90%) and
Dex20-MA(33%) polymers. The NMR analysis for the resulting dextran-peptide hybrids can
be seen in Figure 6, 7, 8, and 9. The NMR analysis suggests final products of Dex20CB(33%)-MA(90%)-R3H3(90%), Dex20-CB(35%)-MA(90%)-R5H5(80%), Dex20-MA(40%)R3H3(40%), and Dex20-MA(20%)-R5H5(40%) respectively.
After running the NMR analysis, the peptide-functionalized dextran hybrids were
conjugated with DNA at N/P ratios (molar ratio of peptide arginine to DNA phosphate) of 0,
1, 5, 10, 20, and 30. Each sample was run in the Zeta-sizer at a temperature of 25°C and at
physiological pH around 8.0. The results of the Zeta-sizer analysis are shown in Figure 10 for
polyplex size and Figure 11 for polyplex zeta-potential. Difficulties were encountered due to
small particles in the ethanol used to wash the Zeta-sizer cuvettes between samples.
Additionally, time and material constraints limited data collection. Titrations and N/P
ratios of 40 were cut and measurement data for R5H5-functionalized polyplexes were limited
to 1 repetition whereas the R3H3-functionalized polyplexes were measured in 3 repetitions.
5. Conclusions
The data suggests that CB-functionalization of dextran leads to greater stability with
DNA as indicated by the zeta-potential of CB-functionalized samples in addition to smaller
polyplex sizes as indicated by the particle size data. Additionally, the data suggests that larger
peptides (more arginine residues) also increase polyplex stability with DNA and generally
decrease the polyplex sizes – the exceptions are non-CB-functionalized dextran at N/P ratios
of 5, 10, and 20.
The author recommends proceeding with this study to gather information on the
effects of dextran molecular weight and degrees of substitution (DMGEE, MA, and peptides).
The author also recommends repeating this particular study to achieve better results as we
12

now have a better understanding of the difficulties encountered during this experiment
(contaminated EtOH wash, improper pipette usage, and procedure intuition).
6. Acknowledgements
Background material research assisted by Matthew Mileusnich. Project oversight
provided by Xia Lei and Dr. Gang Cheng.

13

Scheme 1. Synthetic route of Dex-CB-MA.
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Scheme 2. Conjugation of peptide and DNA.
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Figure 1. 300MHz 1H NMR spectrum of Dex20-CB(33%) in D2O.
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Figure 2. 300MHz 1H NMR spectrum of Dex20-CB(46%)-MA(99%) in D2O.
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Figure 3. 300MHz 1H NMR spectrum of Dex20-CB(35%)-MA(90%) in D2O.
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Figure 4. 300MHz 1H NMR spectrum of Dex20-CB(25%) in D2O.
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Figure 5. 300MHz 1H NMR spectrum of Dex20-MA(33%) in D2O.
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Figure 6. 300MHz 1H NMR spectrum of Dex20-CB(33%)-MA(90%)-R3H3(90%) in D2O.
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Figure 7. 300MHz 1H NMR spectrum of Dex20-CB(35%)-MA(90%)-R5H5(80%) in D2O.
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Figure 8. 300MHz 1H NMR spectrum of Dex20-MA(40%)-R3H3(40%) in D2O.
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Figure 9. 300MHz 1H NMR spectrum of Dex20-MA(20%)-R5H5(40%) in D2O.
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Figure 10. Zeta-Sizer data for polyplex size.
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Figure 11. Zeta-Sizer data for polyplex Zeta-potential.
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Dex20-R3H3(40)
N/P
0
1
5
10
20
30

Size
53.29
1970.00
2067.00
1357.00
1423.00
1193.00

StDev
Zeta Potential
26.60
-28.40
254.20
-14.00
387.20
1.57
532.00
2.37
565.30
3.11
362.40
3.67

StDev
4.51
6.76
3.00
0.76
0.52
0.37

Table 1. Tabulated size and zeta-potential data for Dex20-R3H3(40).

Dex20-CB33-R3H3(90)
N/P
0
1
5
10
20
30

Size
32.86
306.60
920.70
1164.00
1426.00
1439.00

StDev
Zeta Potential
25.00
-17.90
227.40
-25.30
223.30
8.96
304.30
11.10
303.30
12.10
397.10
12.90

StDev
8.87
16.30
1.19
0.79
1.05
0.75

Table 2. Tabulated size and zeta-potential data for Dex20-CB33-R3H3(90).

Dex20-R5H5(40)
N/P
0
1
5
10
20
30

Size
45.35
1199.00
2297.00
2116.00
1897.00
426.10

StDev
Zeta Potential
16.76
-26.40
111.80
-18.50
263.20
8.09
318.50
9.94
296.80
11.60
73.71
14.50

StDev
3.54
2.11
0.38
0.88
1.11
0.72

Table 3. Tabulated size and zeta-potential data for Dex20-R5H5(40).

Dex20-CB35-R5H5(80)
N/P
0
1
5
10
20
30
40

Size
41.58
311.10
216.90
383.70
352.10
321.50
287.20

StDev
Zeta Potential
25.49
-29.70
13.34
-37.70
14.84
9.56
24.57
12.10
10.41
12.90
10.90
14.30
4.97
13.80

StDev
0.87
2.21
0.34
0.77
0.51
0.85
0.44

Table 4. Tabulated size and zeta-potential data for Dex20-CB35-R5H5(80).
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